Complete financial analysis of Parenteral Drugs (India) Limited (PDPL.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Parenteral Drugs (India) Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Xcel Energy Inc. (0M1R.L) Income Statement Analysis – Financial Results
- Goldenbridge Acquisition Limited (GBRG) Income Statement Analysis – Financial Results
- TSH Biopharm Corporation Limited (8432.TWO) Income Statement Analysis – Financial Results
- Maxpro Capital Acquisition Corp. (JMAC) Income Statement Analysis – Financial Results
- Thai Union Group Public Company Limited (TUFUF) Income Statement Analysis – Financial Results
Parenteral Drugs (India) Limited (PDPL.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.pdindia.com
About Parenteral Drugs (India) Limited
Parenteral Drugs (India) Limited operates as a healthcare company in India. The company manufactures pharmaceutical products, including intravenous infusion, inhalation, veterinary infusion, etc. It also offers IV fluids, such as carbohydrates and electrolytes, diuretics, dialysis and irrigation solutions, anti-infective and anti-fungal products, and others; and oncology and anaesthesia products. The company also exports its products to Iraq, Yemen, Mozambique, Ghana, Kenya, Kyrgyzstan, Uzbekistan, Sudan, Vietnam, Cambodia, Liberia, Sri Lanka, Nepal, Myanmar, and Cameroon. The company was incorporated in 1983 and is based in Indore, India.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.96M | 121.53M | 240.25M | 319.98M | 2.17B | 2.30B | 2.47B | 2.51B | 2.58B | 3.09B | 3.33B | 4.87B | 4.14B | 2.69B | 2.13B | 1.73B | 1.32B |
| Cost of Revenue | 54.66M | 73.16M | 226.85M | 244.34M | 1.80B | 1.78B | 2.18B | 1.63B | 2.11B | 2.46B | 1.85B | 3.19B | 2.28B | 1.29B | 893.68M | 786.90M | 570.80M |
| Gross Profit | 30.31M | 48.37M | 13.40M | 75.64M | 370.93M | 519.82M | 293.94M | 878.74M | 465.77M | 629.58M | 1.47B | 1.68B | 1.87B | 1.40B | 1.24B | 947.60M | 752.20M |
| Gross Profit Ratio | 35.67% | 39.80% | 5.58% | 23.64% | 17.11% | 22.63% | 11.89% | 34.99% | 18.07% | 20.35% | 44.35% | 34.49% | 45.11% | 52.01% | 58.04% | 54.63% | 56.86% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 9.36M | 10.26M | 15.45M | 36.79M | 64.79M | 68.64M | 66.84M | 88.91M | 83.69M | 0.00 | 279.67M | 496.40M | 422.33M | 394.64M | 376.90M | 335.90M |
| Selling & Marketing | 0.00 | 7.42M | 24.29M | 30.06M | 270.25M | 164.63M | 190.09M | 451.44M | 494.15M | 544.98M | 0.00 | 685.15M | 589.81M | 474.02M | 390.88M | 346.00M | 270.60M |
| SG&A | 147.87M | 16.78M | 34.54M | 45.51M | 307.05M | 229.42M | 258.73M | 518.27M | 583.07M | 628.67M | 0.00 | 964.82M | 1.09B | 896.34M | 785.52M | 722.90M | 606.50M |
| Other Expenses | 0.00 | 19.18K | 1.73M | 13.39M | 13.37M | 24.45M | 17.27M | 8.15M | 3.26M | 1.00K | 1.48B | 335.21M | 211.16M | 174.96M | 107.96M | 83.60M | 70.60M |
| Operating Expenses | 147.87M | 338.86M | 329.28M | 943.42M | 796.06M | 787.91M | 859.11M | 1.05B | 946.65M | 997.70M | 1.48B | 1.30B | 1.30B | 1.07B | 893.48M | 806.50M | 677.10M |
| Cost & Expenses | 202.53M | 412.02M | 556.14M | 1.19B | 2.59B | 2.57B | 3.04B | 2.68B | 3.06B | 3.46B | 3.33B | 4.49B | 3.57B | 2.36B | 1.79B | 1.59B | 1.25B |
| Interest Income | 0.00 | 618.56K | 789.25K | 961.45K | 2.56M | 3.48M | 3.26M | 1.49M | 37.39M | 2.45M | 443.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.06B | 1.25B | 1.10B | 960.39M | 958.31M | 845.17M | 677.16M | 684.99M | 580.59M | 540.43M | 448.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 401.48M | 173.26M | 173.46M | 691.19M | 242.43M | 248.85M | 227.90M | 309.79M | 186.24M | 229.96M | 144.68M | 125.70M | 90.30M | 70.32M | 44.63M | 27.73M | 22.93M |
| EBITDA | 372.69M | -117.09M | -144.39M | -162.40M | -12.93M | -179.85M | -364.01M | 131.18M | -275.41M | -155.78M | 144.36K | 503.71M | 662.41M | 400.11M | 387.24M | 168.83M | 98.30M |
| EBITDA Ratio | 438.65% | -95.96% | -58.26% | -50.75% | -8.48% | -0.18% | -14.20% | 5.22% | -10.68% | -5.04% | 4.32% | 10.35% | 15.98% | 14.85% | 18.18% | 9.73% | 7.43% |
| Operating Income | 0.00 | -290.99K | -320.32K | -867.78K | -425.13M | -1.28B | -1.29B | -871.75M | -468.88M | -926.17M | -1.13M | 92.51M | 572.12M | 329.79M | 342.60M | 141.10M | 75.10M |
| Operating Income Ratio | 0.00% | -0.24% | -0.13% | -0.27% | -19.61% | -55.70% | -52.02% | -34.71% | -18.19% | -29.94% | -0.03% | 1.90% | 13.80% | 12.24% | 16.09% | 8.13% | 5.68% |
| Total Other Income/Expenses | -973.70M | -1.54B | -1.42B | -946.19M | -987.37M | -1.74B | -1.85B | -1.95B | 3.26M | -870.09M | -484.06M | 263.00 | -174.82M | -154.43M | -107.82M | -65.92M | -53.20M |
| Income Before Tax | -1.09B | -1.54B | -1.42B | -1.81B | -1.41B | -1.26B | -1.27B | -863.60M | -465.62M | -926.17M | -485.20M | 92.51M | 397.30M | 188.32M | 234.88M | 75.00M | 21.90M |
| Income Before Tax Ratio | -1,284.39% | -1,271.11% | -589.95% | -566.90% | -65.15% | -54.63% | -51.32% | -34.39% | -18.06% | -29.94% | -14.59% | 1.90% | 9.59% | 6.99% | 11.03% | 4.32% | 1.66% |
| Income Tax Expense | -327.64M | -327.59M | -276.63M | -334.91M | -223.08M | -102.99M | -103.58M | -186.99M | -13.92M | 152.20M | 48.44M | 42.44M | 92.86M | 71.51M | 43.48M | 27.30M | 11.10M |
| Net Income | -763.62M | -1.22B | -1.14B | -1.48B | -1.19B | -1.15B | -1.17B | -676.61M | -451.70M | -1.08B | -533.78M | 50.07M | 304.44M | 116.81M | 191.40M | 47.60M | 14.10M |
| Net Income Ratio | -898.77% | -1,001.55% | -474.81% | -462.23% | -54.86% | -50.15% | -47.13% | -26.94% | -17.52% | -34.86% | -16.05% | 1.03% | 7.35% | 4.34% | 8.99% | 2.74% | 1.07% |
| EPS | -25.61 | -40.82 | -38.26 | -49.61 | -39.89 | -38.64 | -39.09 | -22.69 | -15.15 | -41.69 | -20.64 | 1.71 | 16.11 | 5.59 | 12.57 | 3.19 | 0.95 |
| EPS Diluted | -25.61 | -40.82 | -38.26 | -49.61 | -39.89 | -38.64 | -39.09 | -22.69 | -15.15 | -41.69 | -20.64 | 1.71 | 16.11 | 5.59 | 12.57 | 3.19 | 0.95 |
| Weighted Avg Shares Out | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 25.87M | 25.87M | 25.85M | 18.90M | 20.91M | 15.23M | 14.93M | 14.92M |
| Weighted Avg Shares Out (Dil) | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 29.82M | 25.87M | 25.87M | 25.85M | 18.90M | 20.91M | 15.23M | 14.93M | 14.92M |
Source: https://incomestatements.info
Category: Stock Reports